Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 22nd Annual BIO CEO & Investor Conference in New York, NY on Tuesday, February 11, 2020 at 11:00 a.m. ET in the Odets room (4th floor) at the New York Marriott Marquis.

BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. Sponsored by the Biotechnology Innovation Organization, the world’s largest biotech trade association, BIO CEO provides a forum where institutional investors, industry analysts and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil, Colombia, the United Arab Emirates and Japan, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago®/safinamide for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com

Contacts

Newron
Stefan Weber – CEO 
+39 02 6103 46 26 
pr@newron.com

UK/Europe 
Simon Conway/ Natalie Garland-Collins, FTI Consulting 
+44 20 3727 1000 
SCnewron@fticonsulting.com

Switzerland
Martin Meier-Pfister, IRF 
+41 43 244 81 40 
meier-pfister@irf-reputation.ch

Germany/Europe
Anne Hennecke, MC Services 
+49 211 52925222 
anne.hennecke@mc-services.eu

USA
Paul Sagan, LaVoieHealthScience 
+1 617 374 8800, Ext. 112 
psagan@lavoiehealthscience.com

 
 

Source: Newron Pharmaceuticals

Back to news